Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This review explores the immunopharmacological potential of A. lappa for inflammatory musculoskeletal disorders (IMSDs) but reports no new clinical results, emphasizing the need for standardized research methodologies.

This study suggests that Acrotrema arnottianum, a herb used in traditional medicine, contains biologically active metabolites like squalene and α-Tocopherol. It showed antibacterial effects against Staphylococcus aureus and antifungal properties against Candida albicans, while demonstrating antioxidant activity.

This study provides evidence that root hairs significantly enhance phosphorus uptake in barley when phosphorus availability is limited in the root zone.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

This study found that supplementing with 1.5% α-ketoglutaric acid significantly improved the performance, hair follicle density, and antioxidant capacity in Rex rabbits, potentially by enhancing the Wnt signaling pathway and reducing amino acid catabolism.

Deoxyshikonin from Arnebiae Radix helps hair grow by activating a specific cell pathway.

This study demonstrated that AtVLN4 plays a role in root hair growth by regulating actin organization in a calcium-dependent manner.

In this study, the combination of arsenic toxicity and hypoxia in Arabidopsis thaliana altered root development through stress-specific root growth phenotypes and changes in phosphate starvation response, energy metabolism, and redox signaling.

In this study, researchers using Arabidopsis thaliana found that adenosine may inhibit root hair growth and stomatal opening, suggesting it plays a signaling role in plants similar to its function in animal cells, potentially revealing a new adenosine-like receptor pathway.

The study found that exposing Arbas Cashmere goats to a short photoperiod significantly increased cashmere production by extending the anagen phase of hair follicles, with gene expression changes identified as contributing factors.

In this study, the pi4kβ1β2 double mutant in Arabidopsis thaliana exhibited altered root growth, increased susceptibility to Blumeria graminis, and a potential correlation between PI4K activity and auxin response and immunity due to changes in vesicular trafficking and actin filaments.

In this study, researchers found that AGD1 is crucial for membrane recruitment during root hair development in Arabidopsis thaliana, with its pleckstrin homology domain essential for targeting specific plasma membrane regions.

This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.

This study found that arctiin, a compound from Arctium lappa, demonstrated protective effects against oxidative stress-induced dysfunction in human hair dermal papilla cells, suggesting potential therapeutic use for alopecia.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

This study found that lateral root formation in plants in response to L. bicolor volatiles involves complex signaling processes, potentially including unknown proteins, CRKs, and ABA pathways.

This study used the "ARE-Luc" mouse model to visualize androgen receptor activity across various tissues in both male and female mice, highlighting the direct action of androgens outside reproductive organs.

Blood pressure medications may increase the risk of skin cancer.

This study reports that TFM-4AS-1, a selective androgen receptor modulator, promoted bone and muscle growth with reduced effects on reproductive organs in ovariectomized rats.

This study reports that AhR pathway expression is significantly reduced in lymphocytes of alopecia areata patients, suggesting its potential as a diagnostic marker and therapeutic target.

In this study, the researchers reported that the optimized compound 39 demonstrated potent AR antagonism and favorable pharmacokinetics in a hair-growth mouse model, achieving similar efficacy to pyrilutamide with faster onset and preserved safety, offering promise for next-generation topical AR antagonist development.

This review examines the patent literature on AKR1C3 inhibitors and suggests that although numerous potent inhibitors exist, further preclinical optimization is necessary before assessing their therapeutic potential in human diseases.

This study by Gao et al. reports that two nonsteroidal selective androgen receptor modulators, S1 and S4, demonstrated tissue-selective actions in rats, suppressing prostate growth while maintaining muscle growth without altering hormone levels.

5-ARI therapy may help prevent prostate cancer progression.

This study identified that downregulation of the gene BcFLA1 decreases root hair length in Brassica carinata under phosphate-deficient conditions, highlighting its role in root hair elongation.

In this study, a novel AR protein degrader was shown to reverse DHT-induced hair regrowth delay in a mouse model of androgenetic alopecia, with minimal circulation and potential side effects.

This study suggests that ROXYs and reactive oxygen species are likely involved in the signaling pathways plants use to respond to nitrate deprivation.

In this study, researchers optimized the soft drug AR antagonist 14-P1 to create candidate 39, which demonstrated effective AR antagonism and safety in a hair-growth mouse model, showing similar efficacy to pyrilutamide but with quicker onset and a lower risk of systemic toxicity.

This study found that patients with alopecia areata showing low treatment burden responded better to baricitinib compared to those with higher previous systemic treatment exposure.